Last reviewed · How we verify
NCT06021431
Digital Therapeutic Development of Virtual Cognitive-Affective Training for Opioid Use Disorder: A Phase 2 Randomized Controlled Trial
NA trial testing MORE-VR in Opioid Use Disorder in 128 participants. Participants enrolled and being followed up; not accepting new ones.
1 August 2025
Quick facts
| Lead sponsor | BehaVR LLC |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 128 |
| Start date | 7 September 2023 |
| Primary completion | 1 August 2025 |
| Estimated completion | 1 September 2025 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- MORE-VR
- Treatment as Usual
Conditions studied
- Opioid Use Disorder — all drugs for Opioid Use Disorder →
Sponsor
BehaVR LLC
Who can join
18 and older, any sex, with Opioid Use Disorder. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Days of opioid use
Time frame: Baseline to post-treatment assessment (8 weeks)
Days of opioid use assessed with the Timeline Followback method, ecological momentary assessments, and/or drug toxicology screen
Sponsor's own description
The goal of this clinical trial is to examine the usefulness of a virtual reality-delivered intervention for individuals with opioid use disorder who are taking medication. The main question it aims to answer is will people with opioid use disorder who receive the study intervention, Mindfulness-Oriented Recovery Enhancement in Virtual Reality (MORE-VR), have fewer days in which they use opioids than will people who just receive their usual treatment. Participants will be randomly assigned to either receive 8 weekly sessions of MORE-VR in addition to their usual treatment, or treatment as usual only. Researchers will compare these groups at the end of treatment and three months after treatment is over on number of days of opioid use and time until first opioid use lapse, as well as drug craving and mood.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06021431
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of MORE-VR
Trials testing the same drug.
- NCT05034276 — Digital Therapeutic Development of Virtual Cognitive-Affective Training for Opioid Use Disorder · NA · completed
Other recruiting trials for Opioid Use Disorder
Currently open trials in the same condition.
- NCT07278518 — Evaluation of a Patient Decision Aid for Emergency Department Initiated Buprenorphine · NA · recruiting
- NCT07044466 — Social Functioning in Opioid Use Disorder · NA · recruiting
- NCT07158853 — Combined tDCS and Cognitive Training as an Adjunctive Treatment in Opioid Use Disorder · NA · recruiting
- NCT06943859 — Ketamine for Opioid Use Disorder · Phase 2 · recruiting
- NCT06651177 — Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06021431 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by BehaVR LLC
- Last refreshed: 28 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06021431.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing